Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Repligen Corporation is a global bioprocessing company that develops and commercia...
Repligen Corporation is a global bioprocessing ...
Surface Oncology is an immuno-oncology company on a mission to break through and d...
Surface Oncology is an immuno-oncology company ...
Axogen (AXGN) is a global leader in innovative surgical solutions for peripheral n...
Axogen (AXGN) is a global leader in innovative ...
Neuralstem is a biopharmaceutical company developing novel treatments for nervous ...
Neuralstem is a biopharmaceutical company devel...
The Medicines Company is a biopharmaceutical company driven by an overriding purpo...
The Medicines Company is a biopharmaceutical co...
Axovant is accelerating the development of innovative gene therapy products that a...
Axovant is accelerating the development of inno...
Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...
Kazia Therapeutics is an oncology-focused biote...
Exicure, Inc. is a clinical stage biotechnology company developing a new class of ...
Exicure, Inc. is a clinical stage biotechnology...
Join the National Investor Network and get the latest information with your interests in mind.